USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR … – Business Wire (press release)
|
USPTO rejects new reexamination request against Celyad's US Patent for Production of Allogeneic TCR-Deficient CAR …
Business Wire (press release) 9,181,527, relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a CAR. The patent remains valid and enforceable. “This is the fourth time that our US Patent for Production of Allogeneic TCR-Deficient CAR–T … |
